Search - tctmd.com

Displaying 1 - 20 of 63

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

News Conference News TCT 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

Yael L. Maxwell

October 28, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

October 31, 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

October 28, 2024

TCT 248: Shift in PCI Strategy in the “Post-ISCHEMIA & REVIVED Trials” Era: Single Center Experience

Presentation TCT 2024

TCT 248: Shift in PCI Strategy in the “Post-ISCHEMIA & REVIVED Trials” Era: Single Center Experience

Presenter: MAKOTO TAKEYAMA

October 28, 2024

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

Ongoing Trials in CTO PCI: Ischemia-CTO, Co-CTO, Invest-CTO, STAR

Presentation TCT 2023

Ongoing Trials in CTO PCI: Ischemia-CTO, Co-CTO, Invest-CTO, STAR

Presenter: Anja Oksnes

October 26, 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

News Conference News TCT 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

October 23, 2023

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

News Conference News TCT 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

September 22, 2022

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

November 05, 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

November 04, 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

Debate 2: Pro – The ISCHEMIA Trial Results Do Not Apply to CABG; Our Outcomes Are Different!

Presentation TCT 2021

Debate 2: Pro – The ISCHEMIA Trial Results Do Not Apply to CABG; Our Outcomes Are Different!

Presenter: Mario Gaudino

November 04, 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

News Conference News TCT 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

October 22, 2021

No Cost Savings With Routine FFRCT for New-Onset Chest Pain: FORECAST

News Conference News TCT 2020

No Cost Savings With Routine FFRCT for New-Onset Chest Pain: FORECAST

Michael O'Riordan

October 21, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.